Canaccord Genuity Group Increases Teladoc Health (NYSE:TDOC) Price Target to $11.00

Teladoc Health (NYSE:TDOC) had its price objective lifted by analysts at Canaccord Genuity Group from $10.00 to $11.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 13.70% from the stock’s current price.

A number of other analysts have also recently issued reports on TDOC. Bank of America increased their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Barclays cut their price target on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating for the company in a research note on Thursday, March 26th. Finally, Citigroup boosted their price objective on Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.73.

Teladoc Health Trading Up 2.6%

Shares of NYSE:TDOC opened at $9.68 on Tuesday. The stock has a 50 day moving average of $7.86 and a 200 day moving average of $6.46. The company has a market cap of $1.75 billion, a PE ratio of -9.97 and a beta of 2.10. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.89. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The firm had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. During the same quarter in the previous year, the business posted ($0.53) EPS. Teladoc Health’s revenue was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. As a group, equities research analysts expect that Teladoc Health will post -0.92 EPS for the current year.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 19,132 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. The trade was a 4.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the transaction, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This represents a 9.70% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock worth $299,058 over the last ninety days. 0.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TDOC. Jupiter Asset Management Ltd. grew its holdings in shares of Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after purchasing an additional 2,880,008 shares in the last quarter. Quantinno Capital Management LP increased its position in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider’s stock worth $14,287,000 after purchasing an additional 1,471,631 shares during the last quarter. Pale Fire Capital SE raised its stake in Teladoc Health by 74.8% during the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider’s stock valued at $18,522,000 after purchasing an additional 1,454,288 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Teladoc Health during the fourth quarter valued at $9,156,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.